<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586794</url>
  </required_header>
  <id_info>
    <org_study_id>MP 3.1 Sildenafil</org_study_id>
    <nct_id>NCT00586794</nct_id>
  </id_info>
  <brief_title>Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients</brief_title>
  <official_title>Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Competence Network for Congenital Heart Defects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Competence Network for Congenital Heart Defects</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that&#xD;
      constitutes a great burden at the individual as well as the familial and social level. The&#xD;
      combination of critically increased pulmonary vascular resistance, progressive pressure load&#xD;
      of the right ventricle and disturbance of pulmonary gas exchange result in long-term&#xD;
      polymorbidity. The objective of this study is to provide evidence of improvement of patients&#xD;
      exercise tolerance as well as general conditions by treatment with oral sildenafil as a&#xD;
      specific pulmonary vasodilator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eisenmenger's syndrome presents as a severe clinical picture of polymorbidity that&#xD;
      constitutes a great burden at the individual as well as the familial and social level. The&#xD;
      combination of critically increased pulmonary vascular resistance, progressive pressure load&#xD;
      of the right ventricle and disturbance of pulmonary gas exchange result in long-term&#xD;
      polymorbidity. While the patient's ability to care for him-/ herself gets lost over time, the&#xD;
      financial burden due to the need for medical consultations and hospital stays increases. This&#xD;
      is distressing to both the patient and the family. Usually, death results from cardiac&#xD;
      decompensation in the presence of gradually increasing pulmonary vascular resistance and&#xD;
      hypoxic lesion of organs including the myocardium (Hopkins, AJC 2002).&#xD;
&#xD;
      With a better understanding of the pathophysiology underlying pulmonary hypertension, novel&#xD;
      therapeutic approaches have been developed during the past few years. These include a)&#xD;
      inhibition of the NO-cGMP-degrading type 5 phosphodiesterase (PDE-5) and b) antagonising the&#xD;
      endothelin system (Krum, Curr Opin Investig Drugs 2003). The goal is a dilatation of the&#xD;
      abnormally constricted pulmonary arterial vessels by relaxation of the vascular smooth muscle&#xD;
      cells with a reversal of pulmonary vascular remodelling (Ghofrani, Pneumologie 2002).&#xD;
&#xD;
      Specific drugs affecting pulmonary vascular resistance have been studied. Intravenous&#xD;
      prostacyclin has major disadvantages: high cost, tachyphylaxis, risk of infection and rebound&#xD;
      hypertension upon discontinuation. Inhalative pulmonary vasodilators, in particular iloprost,&#xD;
      may be effective in primary pulmonary hypertension (Olschewski, Ann Int Med 1996; Hoeper,&#xD;
      Pneumologie 2001), but administration is time-consuming, and due to its mode of application&#xD;
      its effects are intermittent, lasting only about 75 minutes (Hoeper, JACC 2000). Considering&#xD;
      this, oral treatments appear preferable, because of easy administration and, hence, better&#xD;
      patient compliance.&#xD;
&#xD;
      Sildenafil (Revatio®) an inhibitor of the phosphodiesterase 5 (PDE-5) was used in many&#xD;
      individual cases (Abrams, Schulze-Neick et al, Heart 2000), some acute studies and two&#xD;
      long-term studies in humans to reduce the pulmonary vessel resistance. Significant effects on&#xD;
      reduction of the pulmonary vessel resistance were demonstrated for the combination with an&#xD;
      inhalational prostanoid (Ghofrani et al, Ann Int Med 2002).Good long-term tolerability and&#xD;
      effectiveness over a period of two year were demonstrated by this working group.&#xD;
&#xD;
      The objective of this study is to provide evidence of improvement of patients exercise&#xD;
      tolerance as well as general conditions by treatment with oral sildenafil as a specific&#xD;
      pulmonary vasodilator. The data obtained are supposed to contribute to the development of&#xD;
      guidelines for the treatment of Pulmonary Arterial Hypertension (PAH)caused by congenital&#xD;
      heart defects.&#xD;
&#xD;
      The hypotheses are:&#xD;
&#xD;
        1. Sildenafil heales specific pulmonary vascular damage, which occurs by hypercirculation&#xD;
           as quick-acting inhibiting vasoconstriction.&#xD;
&#xD;
        2. Through this there will be a reduction of pulmonary vessel resistance and a&#xD;
           normalization of pulmonary reagibility in patients with Eisenmenger syndrome.&#xD;
&#xD;
        3. Pulmonary blood circulation and so systemic arterial oxygen delivery will increase.&#xD;
&#xD;
        4. The patient benefits from this by improving his exercise tolerance as well as general&#xD;
           and clinical condition.&#xD;
&#xD;
      These hypotheses will be tested by comparing findings of the following examinations before,&#xD;
      during and after the 52 or 78-week treatment with sildenafil: clinical examination,&#xD;
      Electrocardiogram (ECG), echocardiography, ergospirometry, Magnetic Resonance Imaging (MRI),&#xD;
      cardiac catheterization with pulmonary artery manometry, and laboratory tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the distance of walking, which is performed during a 6- min walking test; oxygen saturation and relation of resistance Rp : Rs during the examination with &quot;Herzkatheter&quot;, described as the difference between visit 1 (baseline) and visit 4</measure>
    <time_frame>visit 1 and visit 4 (after 26 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide normalization of pulmonary vascular function (reagibility and vasoactive mediators) in dependence on duration of the therapy</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters of MRI and Echo-diagnostic</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36)</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance of the treatment</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pulmonary Arterial Hypertension (PAH)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>from the 26th weeks on open-label, all patients were treated with Sildenafil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>3x per day 20 mg TID</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Revatio®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3x per day, 20 mg TID</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Non-specific:&#xD;
&#xD;
          1. Written informed consent obtained.&#xD;
&#xD;
          2. No participation in another AMG driven study attendancing this treatment protocol&#xD;
&#xD;
        Specific:&#xD;
&#xD;
          1. Age at least 14 years&#xD;
&#xD;
          2. Presence of cyanosis with &lt; 93 % arterial oxygen saturation (measured by&#xD;
             transcutaneous pulse oximetry)&#xD;
&#xD;
          3. Clinical indication for the invasive diagnostic procedures planned for the study is&#xD;
             given; this is evaluated on the basis of observation before, during and after&#xD;
             medicinal therapy)&#xD;
&#xD;
          4. Presence of PAH as diagnosed by invasive methods with Rp:Rs &gt; 0.5 measured at rest,&#xD;
             before testing of pulmonary vasodilatory reserve&#xD;
&#xD;
          5. One of the following diagnoses:&#xD;
&#xD;
               1. non-corrected large congenital shunting defect at atrial, ventricular or arterial&#xD;
                  level:&#xD;
&#xD;
                    -  PAPVD&#xD;
&#xD;
                    -  ASD&#xD;
&#xD;
                    -  SVD&#xD;
&#xD;
                    -  VSD&#xD;
&#xD;
                    -  AVSD&#xD;
&#xD;
                    -  TAC&#xD;
&#xD;
                    -  APW&#xD;
&#xD;
                    -  PDA&#xD;
&#xD;
                    -  combinations thereof.&#xD;
&#xD;
               2. Surgically corrected shunting defect (diagnoses as above) with significant&#xD;
                  residual defect&#xD;
&#xD;
               3. Other diagnoses with univentricular physiology/ hemodynamics.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Non-specific:&#xD;
&#xD;
          1. pregnancy or lactation&#xD;
&#xD;
          2. women of child-bearing age who are sexually active without practising highly effective&#xD;
             methods of contraception&#xD;
&#xD;
          3. any diseases or impairment that, in the opinion of the investigator exclude a subject&#xD;
             from participation&#xD;
&#xD;
          4. substance abuse (alcohol, medicines, drugs)&#xD;
&#xD;
          5. other medical, psychological or social circumstances that would adversely affect a&#xD;
             patient's ability to participate reliably in the study or increase the risk to&#xD;
             themselves or others if they participated&#xD;
&#xD;
          6. insufficient compliance&#xD;
&#xD;
          7. missing willingness to storaging and transferring pseudonymous disease data within&#xD;
             this study.&#xD;
&#xD;
          8. subjects who are not able to perform Cardio-Pulmonary Exercise Testing (CPX).&#xD;
&#xD;
        Specific:&#xD;
&#xD;
          1. pulmonary hypertension secondary to any etiology other than those specified in the&#xD;
             inclusion criteria&#xD;
&#xD;
          2. subjects with known intolerance of NO and iloprost or their constituents&#xD;
&#xD;
          3. acute decompensated heart failure within the 7 days before the invasive diagnostic&#xD;
             procedure&#xD;
&#xD;
          4. clinically significant haemoptysis within the last 6 months&#xD;
&#xD;
          5. hemodynamic instability which would represent an unjustifiable risk during testing of&#xD;
             pulmonary arterial vasoreagibility&#xD;
&#xD;
          6. arterial hypotension (as defined by age-specific values)&#xD;
&#xD;
          7. anemia (Hb &lt; 10 g/dl)&#xD;
&#xD;
          8. decompensated symptomatic policythemia; (details: 4.2.2. exclusion criteria)&#xD;
&#xD;
          9. thrombocytopenia (&lt; 50.000/µl)&#xD;
&#xD;
         10. secondary impairment of organic function:&#xD;
&#xD;
               -  impairment of renal function (GFR &lt; 30 ml/min/1,73 m2 BSA)&#xD;
&#xD;
               -  impairment of hepatic function (ALT and/or AST &gt; 3 x ULN and bilirubin ≥ 2 mg/dl)&#xD;
&#xD;
         11. other sources of pulmonary blood flow which prohibit measurement of the blood flow&#xD;
             into the lungs and therefore of the pulmonary vascular resistance:&#xD;
&#xD;
               -  Glenn&#xD;
&#xD;
               -  BT shunt&#xD;
&#xD;
               -  significant number of MAPCAs; (details: 4.2.2. exclusion criteria)&#xD;
&#xD;
         12. Obstruction of pulmonary blood outflow:&#xD;
&#xD;
               -  obstruction of pulmonary venous return&#xD;
&#xD;
               -  mitral valve dysfunction&#xD;
&#xD;
         13. Left heart diseases:&#xD;
&#xD;
               -  aortic or mitral valve disease (more severe than &quot;mild&quot;)&#xD;
&#xD;
               -  restrictive or congestive cardiomyopathy&#xD;
&#xD;
               -  PCWP/LVEDP &gt; 15 mmHg&#xD;
&#xD;
               -  symptomatic coronary artery disease&#xD;
&#xD;
         14. Significant valvular diseases other than tricuspid or pulmonary regurgitation (these&#xD;
             are not exclusion criteria; details: 4.2.2. exclusion criteria).&#xD;
&#xD;
         15. Pericardial constriction&#xD;
&#xD;
         16. History of stroke, myocardial infarction or life-threatening arrhythmia within the 6&#xD;
             months before screening&#xD;
&#xD;
         17. Bronchopulmonary dysplasia (BPD) and other chronic lung diseases&#xD;
&#xD;
         18. History of significant pulmonary embolism&#xD;
&#xD;
         19. Other relevant diseases (e.g. HIV, diabetes mellitus requiring medical treatment)&#xD;
&#xD;
         20. Subjects with trisomy 21 (reproducibility of 6-MWT and CPX doubtful; communication as&#xD;
             to side effects and subjective quality of life doubtful)&#xD;
&#xD;
         21. all contraindications against the study medication (see also &quot;4.2.3 concomitant&#xD;
             medication&quot;)&#xD;
&#xD;
               -  hypersensitivity against the active ingredients as well as supplementaries&#xD;
&#xD;
               -  patients who lost vision on one eye due to a non arteriitic anterior ischaemic&#xD;
                  neuropathy of the opticus (NAION).&#xD;
&#xD;
        Prohibited concomitant medication:&#xD;
&#xD;
        Any medication listed below which has not been discontinued at least 30 days prior to&#xD;
        screening. Specific pulmonary vasodilators during cardiac catheterization are allowed.&#xD;
&#xD;
          1. Unspecified concomitant medication&#xD;
&#xD;
          2. Other significant medication (a.o. chronic intake of systemic immunosuppression as&#xD;
             e.g. systemic glucocorticoids, cytostatic drugs, ciclosporin)&#xD;
&#xD;
          3. Instable medication (details: 4.2.5 prohibited concomitant medication):&#xD;
&#xD;
               -  begin of a new medication regimen within the last 30 days before screening&#xD;
&#xD;
               -  change in the dosage of existing medication within the last 7 days before cardiac&#xD;
                  catheterization&#xD;
&#xD;
          4. Existing anti-pulmonary hypertensive medication (in any form) with:&#xD;
&#xD;
               -  PDE-5 antagonists (e.g. sildenafil)&#xD;
&#xD;
               -  prostanoids (e.g. iloprost, prostacyclin, beraprost) In case the patient is&#xD;
                  stable and on Bosentan therapy at least for 6 months. Bosentan (Tracleer®) is&#xD;
                  unprohibited as concomitant medication.&#xD;
&#xD;
          5. Other medication with vascular action:&#xD;
&#xD;
               -  alpha blockers&#xD;
&#xD;
               -  L-arginin (acts through NO axis)&#xD;
&#xD;
               -  ritonavir, nicorandil (act through K+ channels)&#xD;
&#xD;
          6. Medication that is not compatible with sildenafil or interferes with the metabolism:&#xD;
&#xD;
               -  cytochrome P450-CYP2C9 and CYP3A4 inhibitors (e.g.&#xD;
                  erythromycin/ketoconazole/itraconazole/protease inhibitors)&#xD;
&#xD;
               -  any existing medication that, in the opinion of the investigator, may interfere&#xD;
                  with sildenafil treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siegrun Mebus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Heart Institute Munich, Competence Network for Congenital Heart Defects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingram Schulze-Neick, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Great Ormond Street Hospital for Sick Children,London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Klinik III Päd. Kardiologie</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuertemberg</state>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Heidelberg, Pädiatrische Kardiologie</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuertemberg</state>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik, Abteilung Innere Medizin III</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuertemberg</state>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Olgahospital, Klinik für Kinderheilkunde und Jugendmedizin, Pädiatrie 3</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Klinik für Kinderheilkunde und Jugendmedizin</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>D-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilian-Universität München, Klinikum Großhadern, Abt. Kinderkardiologie und Intensivmedizin</name>
      <address>
        <city>München-Großhadern</city>
        <state>Bavaria</state>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen and Marburg, Zentrum für Kinderheilkunde und Jugendmedizin</name>
      <address>
        <city>Giessen</city>
        <state>Hesse</state>
        <zip>D-35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Abt. für Kardiologie und Angiologie</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Kinderheilkunde, Pädiatrische Kardiologie und Pädiatrische Intensivmedizin</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Kinderkrankenhaus, Zentrum für Kinder- und Jugendmedizin</name>
      <address>
        <city>Oldenburg</city>
        <state>Lower Saxony</state>
        <zip>D-26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>North Rhine-Westphalia</state>
        <zip>D-32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches und Johanniter Klinikum Niederrhein gGmbH, Herzzentrum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <state>North Rhine-Westphalia</state>
        <zip>D-47137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, EMAH-Zentrum</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <state>Saarland</state>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle / Saale</city>
        <state>Saxony-Anhalt</state>
        <zip>D-06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin, Abt. angeborener Herzfehler/Kinderkardiologie</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Charite, Campus Virchow-Klinikum, Otto-Heubner-Centrum für Kinder- und Jugendmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Kinderkardiologische Abteilung, Kinder- und Jugendklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-ahf.de</url>
    <description>(Competence Network for Congenital Heart Defects)</description>
  </link>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. Siegrun Mebus</name_title>
    <organization>DHZB,German Heart Institute Munich, Competence Network for Congenital Heart Defects,</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Eisenmenger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Eisenmenger Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

